Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Carolyn Hendrickson MD, MPH

Carolyn M. Hendrickson MD, MPH

Director of the Medical Intensive Care Unit, Zuckerberg San Francisco General Hospital; Associate Professor, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California

Dr. Hendrickson is a pulmonary and critical care medicine subspecialist with an expertise and research focus in acute lung injury and acute respiratory distress syndrome (ARDS), the most common life-threatening manifestation of COVID-19 disease in the earliest years of the pandemic. She is the medical director of the Medical Intensive Care Unit at Zuckerberg San Francisco General Hospital. In recent years there have been several retrospective studies published showing an association between race and differences in pulse oximeter performance.

Dr. Hendrickson and the EquiOx Team are leading an FDA-sponsored study to measure pulse oximeter bias across a range of skin pigmentation among hospitalized patients. This research program aims to better understand how pulse oximeter performance might be improved to ensure these critical devices perform equally well for all patients regardless of skin pigmentation.


Dr. Hendrickson's work is supported by grant funding from FDA, NIH  (NHLBI and NIAID), and the Department of Defense. She has worked as a paid consultant in clinical trial design for Spring Discovery.  She has no investments or ongoing financial relationships with that company.